Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.

Related Articles:

• Carbidopa/Levodopa: Answers to the Frequently Asked Questions May 21, 2019 Carbidopa/Levodopa: Answers to the Frequently Asked Questions Loss of neurons in the brain that use dopamine to communicate is one of the hallmark features of Parkinson’s disease (PD), causing slowness, stiffness, tremor and balance problems. Replacing the brain’s dopamine is therefore one of the key treatment strategies to help improve the motor symptoms of PD. Dopamine itself does not cross…
• Treating Parkinson’s with Carbidopa/Levodopa November 27, 2020 “If you are always trying to be normal you will never know how amazing you can be.” Maya Angelou “Hope and fear cannot occupy the same space. Invite one to stay.” Maya Angelou Précis: This blog post’s primary goal is to present an overview of Carbidopa/Levodopa (originally named Sinemet) for treating Parkinson’s. A secondary objective was to describe the change in…
• Treating Parkinson’s with Carbidopa/Levodopa November 27, 2020 “If you are always trying to be normal you will never know how amazing you can be.” Maya Angelou “Hope and fear cannot occupy the same space. Invite one to stay.” Maya Angelou Précis: This blog post’s primary goal is to present an overview of Carbidopa/Levodopa (originally named Sinemet) for treating Parkinson’s. A secondary objective was to describe the change in…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Part 1 of 2017 PWR! (Parkinson Wellness Recovery) Retreat: Pictures With Great Memories July 23, 2017 “Just put one foot in front of the other.”  Austin Peck “Coming together is a beginning; keeping together is progress; working together is success.”  Henry Ford Introduction to Part 1: From May 28-June 3, >100 people came to Scottsdale, Arizona for the PWR! Retreat. The final tally had >50 people-with-Parkinson’s, more than 30 care partners and ~20 physical therapists/fitness professionals,…
• 24-hour Levodopa-carbidopa Intestinal Gel Lessened Dyskinesia, Parkinson’s Study Finds November 30, 2018 A 24-hour treatment with a levodopa-carbidopa intestinal gel (LCIG) lessened the duration and functional effect of dyskinesia — involuntary, jerky movements — in Parkinson’s patients, according to a small study. The research, “24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease,” was published in npj Parkinson’s disease. Continuous intra-jejunal (the middle part of the small intestine) infusion with…
• B Vitamins (Folate, B6, B12) Reduce Homocysteine Levels Produced by Carbidopa/Levodopa Therapy September 12, 2017 “The excitement of vitamins, nutrition and metabolism permeated the environment.” Paul D. Boyer “A substance that makes you ill if you don’t eat it.” Albert Szent-Gyorgy Introduction: Claire McLean, an amazing-PT who is vital to my life managing my Parkinson’s, posted a very interesting article about the generation of homocysteine from the metabolism of levodopa to dopamine in the brain.…
• La Asociación Americana de Enfermedad de Parkinson lanza la App Diario de síntomas en con funciones ampliadas November 18, 2020 La App es fácil de usar y ayuda a las personas con la enfermedad de Parkinson realizar un seguimiento de sus síntomas y comunicarse con su equipo de atención médica ¡Una versión en español está disponible! NEW YORK, NY – 18 de noviembre de 2020. The American Parkinson Disease Association (la Asociación Americana de Enfermedad de Parkinson o APDA )…
• Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). October 26, 2016 Related ArticlesGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222 Authors: Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S,…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Is it time to back NAC? October 4, 2019   A lot of Parkinson’s research is focused on antioxidants – molecules that can reduce the level of stress a cell is under when it is not feeling well. One of the most widely discussed antioxidants on Parkinson’s online forums is a molecule called N–acetylcysteine (or NAC). Recently, the results of a small clinical trial – in which NAC was…
• What’s Hot in PD? Choosing Between Subcutaneous Apomorphine Infusions, Intestinal Pumps (Duopa) and Deep Brain Stimulation: Implications of the TOLEDO Trial August 7, 2018 Over time, surgical therapies have improved treatment options for a generation of people with Parkinson’s disease (PD) who experience worsening motor fluctuations and dyskinesia. Lesion therapies, such as deep brain stimulation (DBS), are powerful options for people with these troublesome symptoms. Levodopa/carbidopa intestinal pump therapy (Duopa) provide an option for symptom relief without brain surgery. In this month’s edition of…
• Monthly research review – October 2019 October 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Parkinson's Disease Medication Overview July 3, 2019 Medications for PD fall into three categories. The first category includes drugs that increase the level of dopamine in the brain. The second category of PD drugs affects other neurotransmitters in the body in order to ease some of the symptoms of the disease. The third category of drugs prescribed for PD includes medications that help control the non-motor symptoms…
• Delays in Parkinson’s Treatment Due to Fear of Side Effects a Serious Problem, Neurologist Says April 4, 2019 A fear of the potential side effects of Parkinson’s disease treatments, dubbed “levodopa phobia,” can cause patients and their doctors to delay the use of these therapies, a neurologist says. However, evidence suggests that starting adequate levodopa therapy early is safe, particularly for patients with increased functional disability, according to a lecture by Joseph Jankovic, MD, a professor of neurology…
• What is Parkinson’s Disease Dyskinesia? June 12, 2018 Written by Dr. J. William Langston What is Parkinson’s Disease Dyskinesia? Dyskinesia literally means abnormal movement. Parkinson’s Disease (PD) Dyskinesia, often referred to as levodopa-induced dyskinesia, can be described as uncontrolled jerking, dance-like or wriggling movements. Symptoms range from minor tics to full-body movements. It can be a stand-alone condition; however, in people with Parkinson’s, it is most often associated with…
• Gut Bacteria Ate My Parkinson's Meds June 21, 2019 The dog ate my homework, and gut bacteria ate my Parkinson’s meds. I'm glad it wasn't the other way around. In spite of my poor attempt at humor, this is one of the most interesting scientific discoveries related to Parkinson’s Disease so far this year. No, it does not bring us any closer to a cure, but it is of…
• Mucuna pruriens – a natural remedy for Parkinson’s disease? September 24, 2019 Mucuna pruriens – a natural remedy for Parkinson’s disease? You may have heard about Mucuna pruriens (MP) as a natural remedy for Parkinson’s disease (PD) and are curious about whether this is something that you should try. I will dedicate the blog today to a discussion of MP – what it is and what its use is in Parkinson’s disease…
• CMT-3: A better option than doxy? November 22, 2020 # # # # It has been reported by multiple independent research groups that tetracycline-based antibiotic drugs (such as doxycycline) have exhibited neuroprotective properties in models of Parkinson’s. Translation of these preclinical findings into the clinic has, however, been difficult. In addition, concerns have been expressed that long-term use of such agents could bring forward the emergence of antibiotic resistance…